Granulocyte-colony stimulating factor in the treatment of colchicine poisoning

被引:27
作者
Critchley, JAJH
Critchley, LAH
Yeung, EA
Young, RP
Young, RJ
Chan, TYK
Goh, VKM
机构
[1] CHINESE UNIV HONG KONG,DEPT CLIN PHARMACOL,SHATIN,NEW TERRITORIES,HONG KONG
[2] CHINESE UNIV HONG KONG,DEPT ANAESTHESIA & INTENS CARE,SHATIN,NEW TERRITORIES,HONG KONG
[3] HONG KONG SANAT & HOSP,HAPPY VALLEY,HONG KONG
来源
HUMAN & EXPERIMENTAL TOXICOLOGY | 1997年 / 16卷 / 04期
关键词
colchicine poisoning; pancytopenia; G-CSF; Fab fragments;
D O I
10.1177/096032719701600413
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
1 Colchicine is a highly active alkaloid used in the treatment of gouty arthritis and pseudogout. In overdose colchicine inhibits cell division effecting organs with a high rate of cell turn-over, such as the gastrointestinal tract and bone marrow. Early fatality results from cardiovascular collapse and respiratory failure, however pancytopenia and overwhelming septicaemia can occur later. 2 We describe a case of suicidal ingestion of 25-30 mg of colchicine in a previously healthy 43-year-old woman. Initial symptoms were mainly gastrointestinal. By day 5 she had developed severe pancytopenia and early sepsis, which were successfully treated using granulocyte colony stimulating factor (G-CSF) 600 mu g s.c. 3 In vitro G-CSF is produced by the haematopoietic system. However, G-CSF can now be produced by recombinant DNA cloning technology and thus is available clinically. 4 There is no recognised antidote for colchicine poisoning and treatment is symptomatic. Fab fragments may have a promising future in eliminating colchicine from the body, but are currently not clinically available. In those :patients that survive the initial phase of poisoning, G-CSF offers an effective method of treating the pancytopenia and preventing overwhelming septicaemia. Daily monitoring of the patient's haematological status is strongly recommended.
引用
收藏
页码:229 / 232
页数:4
相关论文
共 19 条
[1]   PHARMACOKINETICS - BIOAVAILABILITY OF COLCHICINE IN HEALTHY MALE-VOLUNTEERS [J].
ACHTERT, G ;
SCHERRMANN, JM ;
CHRISTEN, MO .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1989, 14 (04) :317-322
[2]   TREATMENT OF SEVERE COLCHICINE OVERDOSE WITH COLCHICINE-SPECIFIC FAB FRAGMENTS [J].
BAUD, FJ ;
SABOURAUD, A ;
VICAUT, E ;
TABOULET, P ;
LANG, J ;
BISMUTH, C ;
ROUZIOUX, JM ;
SCHERRMANN, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (10) :642-645
[3]  
BISMUTH C, 1977, NOUV PRESSE MED, V6, P1625
[4]  
BISMUTH C, 1986, J TOXICOL CLIN EXPER, V6, P33
[5]  
CARACO Y, 1992, J RHEUMATOL, V19, P494
[6]  
DAVIES HO, 1988, CAN MED ASSOC J, V138, P335
[7]   COLCHICINE TOXICITY - CLINICAL-FEATURES AND TREATMENT - MASSIVE OVERDOSE CASE-REPORT [J].
FOLPINI, A ;
FURFORI, P .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1995, 33 (01) :71-77
[8]  
FRAYHA RA, 1984, BRIT J RHEUMATOL, V23, P292
[9]  
GABRILOVE JL, 1989, SEMIN HEMATOL, V26, P1
[10]  
GARDEN AL, 1990, NEW ZEAL MED J, V103, P402